Share Price and Basic Stock Data
Last Updated: December 19, 2025, 7:57 pm
| PEG Ratio | 0.52 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Ajooni Biotech Ltd operates in the animal and shrimp feed industry, a sector that has seen varying fortunes in recent years. The company reported ₹74 Cr in sales for FY 2023, a figure that remained unchanged from FY 2022, indicating a plateau in revenue growth. However, looking at the quarterly data, there is a notable spike in the March 2023 quarter, where sales surged to ₹41.26 Cr. This was followed by a decline in subsequent quarters, with sales dropping to ₹19.48 Cr by September 2023. Nevertheless, the latest quarterly figures for June 2024 show a recovery to ₹25.66 Cr, hinting at potential stabilization. Over the years, Ajooni has progressively increased its sales from just ₹1 Cr in FY 2014 to an expected ₹115 Cr in FY 2025, highlighting a long-term growth trajectory, albeit with recent volatility that investors should keep an eye on.
Profitability and Efficiency Metrics
Profitability metrics for Ajooni Biotech reveal a mixed picture. The company’s operating profit margin (OPM) stood at a modest 2.27% as of the latest reporting, which is below industry norms and suggests that the company is struggling to convert sales into profits effectively. The net profit for FY 2023 was reported at ₹4 Cr, translating to an earnings per share (EPS) of ₹0.06. This represents a slight increase from ₹0.05 in FY 2022, but the overall net profit margin of 2.94% for FY 2025 highlights the challenges in maintaining profitability. A notable strength is the interest coverage ratio, which was an impressive 17.22x, indicating that the company is comfortably able to meet its interest obligations. However, the cash conversion cycle (CCC) of 129 days raises concerns about operational efficiency and liquidity, as funds are tied up in inventory and receivables for extended periods.
Balance Sheet Strength and Financial Ratios
Ajooni Biotech’s balance sheet appears relatively stable, with total borrowings reported at ₹9 Cr against reserves of ₹55 Cr. This low level of debt, reflected in a total debt-to-equity ratio of 0.06, indicates a conservative capital structure that may be appealing to risk-averse investors. The company’s current ratio of 12.86 indicates a strong liquidity position, suggesting that Ajooni can easily cover its short-term liabilities. However, the price-to-book value (P/BV) ratio of 1.10x points toward a valuation that could be seen as stretched compared to peers in the sector. A significant risk is the declining return on equity (ROE), which stood at 5.15%, a figure that does not inspire confidence in the company’s ability to generate returns for its shareholders. This, combined with a relatively low return on capital employed (ROCE) of 6.91%, suggests that Ajooni may need to reassess its operational strategies to enhance profitability.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Ajooni Biotech reveals a significant public ownership at 73.11%, with promoters holding 26.89%. The promoters’ stake has seen a gradual decline from 36.39% in December 2022, which raises questions about their confidence in the company’s future prospects. Interestingly, foreign institutional investors (FIIs) have not yet entered the fray, holding 0.00% of shares, while domestic institutional investors (DIIs) remain unreported. This lack of institutional backing may reflect a cautious sentiment toward the stock, particularly given its recent performance metrics. The increasing number of shareholders, which rose to 64,305, indicates growing retail interest. However, the declining promoter stake could deter some investors, as it may signal a lack of commitment from those who know the company best.
Outlook, Risks, and Final Insight
The outlook for Ajooni Biotech remains complex. On one hand, the company has shown remarkable growth in sales over the long term, moving from ₹1 Cr in FY 2014 to anticipated figures of ₹115 Cr in FY 2025. Yet, the recent fluctuations in quarterly sales and profitability metrics raise red flags. The company faces ongoing challenges in operational efficiency, as indicated by its prolonged cash conversion cycle and low profit margins. Potential risks include reliance on a volatile market for animal feed, fluctuating raw material costs, and the need for strategic improvements to bolster profitability. For investors, the decision to engage with Ajooni Biotech should weigh these risks against its long-term growth potential. While the balance sheet appears strong, the declining promoter stake and lack of institutional interest could be concerning factors. Therefore, retail investors might consider closely monitoring upcoming quarterly results and strategic shifts that could impact Ajooni’s financial health.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Narmada Agrobase Ltd | 77.7 Cr. | 21.2 | 28.4/14.6 | 20.3 | 15.3 | 0.00 % | 13.0 % | 11.2 % | 10.0 |
| Godrej Agrovet Ltd | 10,983 Cr. | 571 | 876/560 | 25.2 | 94.1 | 1.93 % | 16.6 % | 17.7 % | 10.0 |
| Avanti Feeds Ltd | 11,639 Cr. | 854 | 965/572 | 18.8 | 221 | 1.05 % | 24.0 % | 19.5 % | 1.00 |
| Ajooni Biotech Ltd | 73.0 Cr. | 4.24 | 8.55/4.16 | 18.4 | 5.21 | 0.00 % | 6.91 % | 5.15 % | 2.00 |
| Industry Average | 11,311.00 Cr | 362.61 | 20.68 | 83.90 | 0.75% | 15.13% | 13.39% | 5.75 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 12.31 | 10.29 | 10.63 | 41.26 | 21.00 | 19.48 | 20.05 | 19.58 | 25.66 | 25.72 | 34.03 | 29.27 | 31.27 |
| Expenses | 11.55 | 9.70 | 10.15 | 40.32 | 20.34 | 18.85 | 20.70 | 17.99 | 24.70 | 24.95 | 33.10 | 28.26 | 30.56 |
| Operating Profit | 0.76 | 0.59 | 0.48 | 0.94 | 0.66 | 0.63 | -0.65 | 1.59 | 0.96 | 0.77 | 0.93 | 1.01 | 0.71 |
| OPM % | 6.17% | 5.73% | 4.52% | 2.28% | 3.14% | 3.23% | -3.24% | 8.12% | 3.74% | 2.99% | 2.73% | 3.45% | 2.27% |
| Other Income | 0.01 | 0.00 | 0.02 | 0.26 | 0.07 | 0.29 | 1.57 | 0.26 | 0.04 | 0.31 | 0.39 | 1.34 | 0.65 |
| Interest | 0.10 | 0.13 | 0.13 | 0.12 | 0.13 | 0.19 | 0.12 | 0.11 | 0.15 | 0.06 | 0.07 | 0.06 | 0.08 |
| Depreciation | 0.25 | 0.25 | 0.26 | 0.24 | 0.21 | 0.21 | 0.21 | 0.24 | 0.22 | 0.23 | 0.24 | 0.38 | 0.25 |
| Profit before tax | 0.42 | 0.21 | 0.11 | 0.84 | 0.39 | 0.52 | 0.59 | 1.50 | 0.63 | 0.79 | 1.01 | 1.91 | 1.03 |
| Tax % | 23.81% | 19.05% | 0.00% | 35.71% | -2.56% | 23.08% | 23.73% | 38.67% | 25.40% | 22.78% | 27.72% | 19.37% | 24.27% |
| Net Profit | 0.32 | 0.16 | 0.11 | 0.54 | 0.40 | 0.40 | 0.44 | 0.91 | 0.47 | 0.62 | 0.73 | 1.54 | 0.78 |
| EPS in Rs | 0.02 | 0.01 | 0.01 | 0.03 | 0.02 | 0.02 | 0.03 | 0.05 | 0.03 | 0.04 | 0.04 | 0.09 | 0.05 |
Last Updated: August 20, 2025, 2:35 pm
Below is a detailed analysis of the quarterly data for Ajooni Biotech Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 31.27 Cr.. The value appears strong and on an upward trend. It has increased from 29.27 Cr. (Mar 2025) to 31.27 Cr., marking an increase of 2.00 Cr..
- For Expenses, as of Jun 2025, the value is 30.56 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 28.26 Cr. (Mar 2025) to 30.56 Cr., marking an increase of 2.30 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.71 Cr.. The value appears to be declining and may need further review. It has decreased from 1.01 Cr. (Mar 2025) to 0.71 Cr., marking a decrease of 0.30 Cr..
- For OPM %, as of Jun 2025, the value is 2.27%. The value appears to be declining and may need further review. It has decreased from 3.45% (Mar 2025) to 2.27%, marking a decrease of 1.18%.
- For Other Income, as of Jun 2025, the value is 0.65 Cr.. The value appears to be declining and may need further review. It has decreased from 1.34 Cr. (Mar 2025) to 0.65 Cr., marking a decrease of 0.69 Cr..
- For Interest, as of Jun 2025, the value is 0.08 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.06 Cr. (Mar 2025) to 0.08 Cr., marking an increase of 0.02 Cr..
- For Depreciation, as of Jun 2025, the value is 0.25 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.38 Cr. (Mar 2025) to 0.25 Cr., marking a decrease of 0.13 Cr..
- For Profit before tax, as of Jun 2025, the value is 1.03 Cr.. The value appears to be declining and may need further review. It has decreased from 1.91 Cr. (Mar 2025) to 1.03 Cr., marking a decrease of 0.88 Cr..
- For Tax %, as of Jun 2025, the value is 24.27%. The value appears to be increasing, which may not be favorable. It has increased from 19.37% (Mar 2025) to 24.27%, marking an increase of 4.90%.
- For Net Profit, as of Jun 2025, the value is 0.78 Cr.. The value appears to be declining and may need further review. It has decreased from 1.54 Cr. (Mar 2025) to 0.78 Cr., marking a decrease of 0.76 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.05. The value appears to be declining and may need further review. It has decreased from 0.09 (Mar 2025) to 0.05, marking a decrease of 0.04.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:44 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1 | 7 | 13 | 29 | 42 | 40 | 40 | 51 | 74 | 74 | 80 | 115 | 126 |
| Expenses | 1 | 7 | 13 | 28 | 41 | 39 | 39 | 49 | 71 | 72 | 78 | 111 | 122 |
| Operating Profit | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 3 | 3 | 2 | 4 | 4 |
| OPM % | 2% | 2% | 2% | 2% | 2% | 2% | 3% | 3% | 4% | 4% | 3% | 3% | 3% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 4 | 5 |
| Tax % | 0% | 27% | 29% | 28% | 20% | 15% | 29% | 26% | 28% | 28% | 28% | 22% | |
| Net Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 3 | 4 |
| EPS in Rs | 0.02 | 0.12 | 0.18 | 0.36 | 0.03 | 0.03 | 0.02 | 0.02 | 0.05 | 0.06 | 0.12 | 0.20 | 0.23 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 100.00% | 50.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 100.00% | -50.00% |
Ajooni Biotech Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 3 years from 2022-2023 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 32% |
| 5 Years: | 23% |
| 3 Years: | 16% |
| TTM: | 42% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 47% |
| 5 Years: | 56% |
| 3 Years: | 47% |
| TTM: | 65% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -7% |
| 3 Years: | -19% |
| 1 Year: | -49% |
| Return on Equity | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 5% |
| 3 Years: | 5% |
| Last Year: | 5% |
Last Updated: September 4, 2025, 9:40 pm
Balance Sheet
Last Updated: December 10, 2025, 2:17 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.24 | 0.24 | 0.24 | 0.33 | 6 | 6 | 8 | 10 | 10 | 18 | 18 | 34 | 34 |
| Reserves | 0 | 0 | 0 | 1 | 5 | 6 | 7 | 6 | 6 | 24 | 25 | 54 | 55 |
| Borrowings | -0 | -0 | 1 | 1 | 5 | 5 | 5 | 7 | 5 | 5 | 2 | 2 | 9 |
| Other Liabilities | 0 | 1 | 1 | 11 | 4 | 1 | 2 | 6 | 7 | 12 | 3 | 5 | 5 |
| Total Liabilities | 0 | 2 | 2 | 13 | 19 | 18 | 23 | 28 | 29 | 59 | 48 | 95 | 104 |
| Fixed Assets | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 5 | 6 | 6 | 10 | 11 | 11 |
| CWIP | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 0 | 1 | 0 | 11 |
| Investments | -0 | -0 | -0 | 6 | 6 | 4 | 3 | 1 | 1 | 4 | 2 | 3 | 3 |
| Other Assets | 0 | 1 | 2 | 6 | 12 | 13 | 18 | 22 | 22 | 48 | 34 | 80 | 78 |
| Total Assets | 0 | 2 | 2 | 13 | 19 | 18 | 23 | 28 | 29 | 59 | 48 | 95 | 104 |
Below is a detailed analysis of the balance sheet data for Ajooni Biotech Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 34.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 34.00 Cr..
- For Reserves, as of Sep 2025, the value is 55.00 Cr.. The value appears strong and on an upward trend. It has increased from 54.00 Cr. (Mar 2025) to 55.00 Cr., marking an increase of 1.00 Cr..
- For Borrowings, as of Sep 2025, the value is 9.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 2.00 Cr. (Mar 2025) to 9.00 Cr., marking an increase of 7.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 5.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 5.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 104.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 95.00 Cr. (Mar 2025) to 104.00 Cr., marking an increase of 9.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 11.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 11.00 Cr..
- For CWIP, as of Sep 2025, the value is 11.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 11.00 Cr., marking an increase of 11.00 Cr..
- For Investments, as of Sep 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
- For Other Assets, as of Sep 2025, the value is 78.00 Cr.. The value appears to be declining and may need further review. It has decreased from 80.00 Cr. (Mar 2025) to 78.00 Cr., marking a decrease of 2.00 Cr..
- For Total Assets, as of Sep 2025, the value is 104.00 Cr.. The value appears strong and on an upward trend. It has increased from 95.00 Cr. (Mar 2025) to 104.00 Cr., marking an increase of 9.00 Cr..
Notably, the Reserves (55.00 Cr.) exceed the Borrowings (9.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 0.00 | 0.00 | -1.00 | 0.00 | -4.00 | -4.00 | -4.00 | -5.00 | -2.00 | -2.00 | 0.00 | 2.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 58 | 40 | 33 | 17 | 25 | 44 | 115 | 98 | 68 | 101 | 59 | 52 |
| Inventory Days | 141 | 22 | 14 | 63 | 19 | 51 | 34 | 46 | 34 | 39 | 80 | 90 |
| Days Payable | 100 | 66 | 27 | 79 | 9 | 12 | 20 | 46 | 39 | 56 | 8 | 13 |
| Cash Conversion Cycle | 99 | -4 | 20 | 1 | 35 | 84 | 129 | 98 | 63 | 83 | 131 | 129 |
| Working Capital Days | 96 | 5 | 9 | -29 | -1 | 84 | 105 | 77 | 58 | 94 | 132 | 160 |
| ROCE % | 28% | 18% | 37% | 10% | 4% | 4% | 5% | 9% | 6% | 8% | 7% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.20 | 0.25 | 1.94 | 1.05 | 0.37 |
| Diluted EPS (Rs.) | 0.20 | 0.25 | 1.94 | 1.05 | 0.37 |
| Cash EPS (Rs.) | 0.25 | 0.34 | 0.24 | 2.16 | 0.95 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 5.11 | 4.87 | 4.76 | 16.37 | 15.64 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 5.11 | 4.87 | 4.76 | 16.37 | 15.64 |
| Revenue From Operations / Share (Rs.) | 6.66 | 9.14 | 8.50 | 74.00 | 51.01 |
| PBDIT / Share (Rs.) | 0.33 | 0.50 | 0.34 | 3.11 | 1.66 |
| PBIT / Share (Rs.) | 0.27 | 0.40 | 0.23 | 2.00 | 1.09 |
| PBT / Share (Rs.) | 0.25 | 0.34 | 0.17 | 1.46 | 0.50 |
| Net Profit / Share (Rs.) | 0.19 | 0.24 | 0.12 | 1.05 | 0.37 |
| PBDIT Margin (%) | 5.01 | 5.52 | 4.10 | 4.20 | 3.26 |
| PBIT Margin (%) | 4.06 | 4.43 | 2.75 | 2.70 | 2.13 |
| PBT Margin (%) | 3.77 | 3.73 | 2.11 | 1.97 | 0.98 |
| Net Profit Margin (%) | 2.94 | 2.69 | 1.50 | 1.41 | 0.73 |
| Return on Networth / Equity (%) | 3.82 | 5.06 | 2.69 | 6.40 | 2.38 |
| Return on Capital Employeed (%) | 5.16 | 7.98 | 4.72 | 10.55 | 6.20 |
| Return On Assets (%) | 3.54 | 4.54 | 1.91 | 3.61 | 1.33 |
| Long Term Debt / Equity (X) | 0.02 | 0.03 | 0.04 | 0.15 | 0.12 |
| Total Debt / Equity (X) | 0.06 | 0.05 | 0.12 | 0.32 | 0.43 |
| Asset Turnover Ratio (%) | 1.61 | 1.51 | 1.70 | 2.60 | 2.00 |
| Current Ratio (X) | 12.86 | 10.74 | 2.28 | 2.18 | 2.05 |
| Quick Ratio (X) | 7.89 | 5.63 | 1.82 | 1.60 | 1.53 |
| Inventory Turnover Ratio (X) | 5.83 | 6.25 | 10.27 | 11.35 | 10.01 |
| Interest Coverage Ratio (X) | 17.22 | 7.95 | 6.40 | 5.76 | 2.85 |
| Interest Coverage Ratio (Post Tax) (X) | 11.09 | 4.88 | 3.35 | 2.94 | 1.64 |
| Enterprise Value (Cr.) | 95.06 | 53.43 | 39.48 | 72.63 | 36.96 |
| EV / Net Operating Revenue (X) | 0.82 | 0.66 | 0.52 | 0.98 | 0.72 |
| EV / EBITDA (X) | 16.51 | 12.07 | 12.90 | 23.34 | 22.19 |
| MarketCap / Net Operating Revenue (X) | 0.84 | 0.64 | 0.46 | 0.90 | 0.59 |
| Price / BV (X) | 1.10 | 1.21 | 0.83 | 4.11 | 1.94 |
| Price / Net Operating Revenue (X) | 0.84 | 0.64 | 0.46 | 0.90 | 0.59 |
| EarningsYield | 0.03 | 0.04 | 0.03 | 0.01 | 0.01 |
After reviewing the key financial ratios for Ajooni Biotech Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.20. This value is below the healthy minimum of 5. It has decreased from 0.25 (Mar 24) to 0.20, marking a decrease of 0.05.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.20. This value is below the healthy minimum of 5. It has decreased from 0.25 (Mar 24) to 0.20, marking a decrease of 0.05.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.25. This value is below the healthy minimum of 3. It has decreased from 0.34 (Mar 24) to 0.25, marking a decrease of 0.09.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 5.11. It has increased from 4.87 (Mar 24) to 5.11, marking an increase of 0.24.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 5.11. It has increased from 4.87 (Mar 24) to 5.11, marking an increase of 0.24.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 6.66. It has decreased from 9.14 (Mar 24) to 6.66, marking a decrease of 2.48.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.33. This value is below the healthy minimum of 2. It has decreased from 0.50 (Mar 24) to 0.33, marking a decrease of 0.17.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.27. This value is within the healthy range. It has decreased from 0.40 (Mar 24) to 0.27, marking a decrease of 0.13.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.25. This value is within the healthy range. It has decreased from 0.34 (Mar 24) to 0.25, marking a decrease of 0.09.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.19. This value is below the healthy minimum of 2. It has decreased from 0.24 (Mar 24) to 0.19, marking a decrease of 0.05.
- For PBDIT Margin (%), as of Mar 25, the value is 5.01. This value is below the healthy minimum of 10. It has decreased from 5.52 (Mar 24) to 5.01, marking a decrease of 0.51.
- For PBIT Margin (%), as of Mar 25, the value is 4.06. This value is below the healthy minimum of 10. It has decreased from 4.43 (Mar 24) to 4.06, marking a decrease of 0.37.
- For PBT Margin (%), as of Mar 25, the value is 3.77. This value is below the healthy minimum of 10. It has increased from 3.73 (Mar 24) to 3.77, marking an increase of 0.04.
- For Net Profit Margin (%), as of Mar 25, the value is 2.94. This value is below the healthy minimum of 5. It has increased from 2.69 (Mar 24) to 2.94, marking an increase of 0.25.
- For Return on Networth / Equity (%), as of Mar 25, the value is 3.82. This value is below the healthy minimum of 15. It has decreased from 5.06 (Mar 24) to 3.82, marking a decrease of 1.24.
- For Return on Capital Employeed (%), as of Mar 25, the value is 5.16. This value is below the healthy minimum of 10. It has decreased from 7.98 (Mar 24) to 5.16, marking a decrease of 2.82.
- For Return On Assets (%), as of Mar 25, the value is 3.54. This value is below the healthy minimum of 5. It has decreased from 4.54 (Mar 24) to 3.54, marking a decrease of 1.00.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. It has decreased from 0.03 (Mar 24) to 0.02, marking a decrease of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.06. This value is within the healthy range. It has increased from 0.05 (Mar 24) to 0.06, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.61. It has increased from 1.51 (Mar 24) to 1.61, marking an increase of 0.10.
- For Current Ratio (X), as of Mar 25, the value is 12.86. This value exceeds the healthy maximum of 3. It has increased from 10.74 (Mar 24) to 12.86, marking an increase of 2.12.
- For Quick Ratio (X), as of Mar 25, the value is 7.89. This value exceeds the healthy maximum of 2. It has increased from 5.63 (Mar 24) to 7.89, marking an increase of 2.26.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.83. This value is within the healthy range. It has decreased from 6.25 (Mar 24) to 5.83, marking a decrease of 0.42.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 17.22. This value is within the healthy range. It has increased from 7.95 (Mar 24) to 17.22, marking an increase of 9.27.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 11.09. This value is within the healthy range. It has increased from 4.88 (Mar 24) to 11.09, marking an increase of 6.21.
- For Enterprise Value (Cr.), as of Mar 25, the value is 95.06. It has increased from 53.43 (Mar 24) to 95.06, marking an increase of 41.63.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.82. This value is below the healthy minimum of 1. It has increased from 0.66 (Mar 24) to 0.82, marking an increase of 0.16.
- For EV / EBITDA (X), as of Mar 25, the value is 16.51. This value exceeds the healthy maximum of 15. It has increased from 12.07 (Mar 24) to 16.51, marking an increase of 4.44.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 1. It has increased from 0.64 (Mar 24) to 0.84, marking an increase of 0.20.
- For Price / BV (X), as of Mar 25, the value is 1.10. This value is within the healthy range. It has decreased from 1.21 (Mar 24) to 1.10, marking a decrease of 0.11.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 1. It has increased from 0.64 (Mar 24) to 0.84, marking an increase of 0.20.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.04 (Mar 24) to 0.03, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Ajooni Biotech Ltd:
- Net Profit Margin: 2.94%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 5.16% (Industry Average ROCE: 15.13%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 3.82% (Industry Average ROE: 13.39%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 11.09
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 7.89
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 18.4 (Industry average Stock P/E: 20.68)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.06
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.94%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Animal/Shrimp Feed | D-118, Industrial Area, Phase - VII, Mohali Punjab 160055 | info@ajoonibiotech.com http://www.ajoonibiotech.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Jasjot Singh | Managing Director & CFO |
| Mr. Gursimran Singh | Whole Time Director |
| Mr. Partek Singh | Director |
| Mr. Ramandeep Singh | Independent Director |
| Mr. Imteshwar Singh | Independent Director |
| Ms. Simmi Chabbra | Independent Director |
| Mr. Ishtneet Bhatia | Independent Director |
FAQ
What is the intrinsic value of Ajooni Biotech Ltd?
Ajooni Biotech Ltd's intrinsic value (as of 19 December 2025) is 4.03 which is 4.95% lower the current market price of 4.24, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 73.0 Cr. market cap, FY2025-2026 high/low of 8.55/4.16, reserves of ₹55 Cr, and liabilities of 104 Cr.
What is the Market Cap of Ajooni Biotech Ltd?
The Market Cap of Ajooni Biotech Ltd is 73.0 Cr..
What is the current Stock Price of Ajooni Biotech Ltd as on 19 December 2025?
The current stock price of Ajooni Biotech Ltd as on 19 December 2025 is 4.24.
What is the High / Low of Ajooni Biotech Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Ajooni Biotech Ltd stocks is 8.55/4.16.
What is the Stock P/E of Ajooni Biotech Ltd?
The Stock P/E of Ajooni Biotech Ltd is 18.4.
What is the Book Value of Ajooni Biotech Ltd?
The Book Value of Ajooni Biotech Ltd is 5.21.
What is the Dividend Yield of Ajooni Biotech Ltd?
The Dividend Yield of Ajooni Biotech Ltd is 0.00 %.
What is the ROCE of Ajooni Biotech Ltd?
The ROCE of Ajooni Biotech Ltd is 6.91 %.
What is the ROE of Ajooni Biotech Ltd?
The ROE of Ajooni Biotech Ltd is 5.15 %.
What is the Face Value of Ajooni Biotech Ltd?
The Face Value of Ajooni Biotech Ltd is 2.00.